Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LIBERTY 1: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Co-Administered With and Without Low-Dose Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03049735 is registered in ClinicalTrials.gov with Myovant Sciences GmbH as lead sponsor.

NCT NCT03049735
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03049735 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LIBERTY 1: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Co-Administered With and Without Low-Dose Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Lead sponsor
Myovant Sciences GmbH
Phase
Phase 3
Overall status
Completed
Start date
April 26, 2017
Completion date
August 24, 2020
Enrollment
388 (actual)
Sites
110

Conditions

As the registry lists them; a condition with its own page is linked.

heavy menstrual bleeding, uterine fibroid